Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1141-1160 of 1,307 trials

Grass Pollen Allergy: CLU-RX-PHL Treatment

We are testing a new subcutaneous treatment for people with grass pollen allergy. The study aims to find the most effective and safest dose to help manage allergy symptoms.

Allergic Rhinitis Due to Pollen6-12 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesAllergologyInternal Medicine

Grass Pollen Allergy: Sublingual Immunotherapy Study

We are evaluating a new sublingual treatment for people with grass pollen allergies to see if it effectively reduces allergy symptoms. The study will also assess the safety of different doses.

Allergic Rhinitis due to PollenEfficacy phase (II)Confirmation phase (III)Investigational MedicinesAllergology

Neovascular Age-Related Macular Degeneration: Faricimab Injections

We are studying the safety and long-term effectiveness of faricimab injections for people with neovascular age-related macular degeneration. The goal is to see if it improves vision and how well it works over time.

Neovascular Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

ALK-Positive Advanced Lung Cancer: NVL-655 vs. Alectinib

We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.

Advanced ALK-positive Non-Small Cell Lung CancerConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Severe Asthma: Dupilumab Treatment Study

We are investigating how Dupilumab affects mucus buildup and immune responses in patients with severe asthma. This study aims to improve understanding of asthma management and treatment options.

Severe Asthma>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

Kidney Transplant: Ravulizumab Study

We are testing Ravulizumab in adults at high risk of delayed graft function after kidney transplantation. The goal is to see if it helps improve kidney function and reduces the need for dialysis.

Delayed Graft Function after Kidney Transplantation1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNephrology

Anesthesia Study: Ketamine vs. Propofol Combinations

We are comparing the effectiveness of ketamine alone and a ketamine-propofol mix against standard propofol for safe tracheal intubation in patients at risk of aspiration during surgery. The goal is to see which option leads to fewer complications and better tolerance.

Rapid Sequence Induction≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry

Central Retinal Artery Occlusion: Tenecteplase Study

We are investigating whether tenecteplase can help improve vision in patients with central retinal artery occlusion when given shortly after symptoms begin. This study compares it to standard treatment to see which is more effective.

Central Retinal Artery Occlusion>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyNeurologyOphthalmology

Cardiovascular Risk: Allopurinol Study

We are investigating if allopurinol can lower cardiovascular risks in patients with high risk, including those experiencing long-COVID. This study focuses on individuals over 60 years old as well.

Heart FailureHypertensionAtrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyEndocrinologyInternal Medicine

Difficult-to-Treat Hypertension: OPTIMAL-HT Study

We are exploring whether a new combination of medications can help people with uncontrolled high blood pressure achieve better control. This study will compare different treatment strategies to find the most effective approach.

High Blood Pressure (Hypertension)OverpressureConfirmation phase (III)Monitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Managing High Potassium: Lokelma for Chronic Kidney Disease

We are studying whether Sodium Zirconium Cyclosilicate (Lokelma) can help lower potassium levels in patients with chronic kidney disease. This trial compares it to standard treatments to find the best approach.

High Potassium Levels in Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Hidradenitis Suppurativa: Ruxolitinib Cream Study

We are evaluating a new cream for people with hidradenitis suppurativa to see if it helps reduce symptoms and is safe to use. This study aims to find out how effective the cream is compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementDermatology

Prostate Cancer: Short vs. Long-Term Androgen Deprivation Therapy

We are comparing short-term and long-term hormone therapy combined with radiotherapy for men with prostate cancer that has returned after surgery. The goal is to see which approach may improve survival and reduce recurrence.

Prostate Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyUrology

Inhaled Sevoflurane for Sedation in Critically Ill Patients

We are studying whether inhaled sevoflurane improves breathing and safety in ICU patients at risk for ARDS compared to standard sedation methods. This research may help us understand better sedation options for these vulnerable patients.

Patients at Risk of Acute Respiratory Distress Syndrome>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPulmonology

Brain Aneurysms: Acetylsalicylic Acid Study

We are studying whether acetylsalicylic acid can lower the risk of stroke and improve cognitive function in patients undergoing treatment for unruptured brain aneurysms. This trial compares ASA with a placebo to assess its safety and effectiveness.

Unruptured Cerebral Aneurysm>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurology

Labor Induction: Oxytocin vs. Prostaglandins

We are studying whether oxytocin is as safe as prostaglandins for inducing labor in women with an unfavorable cervix. This trial will help us understand the risks and benefits of both methods.

Labor Induction>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Ataxia-Telangiectasia: N-Acetyl-L-Leucine Study

We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.

Ataxia Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Dexamethasone for Severe Burns

We are studying whether early treatment with dexamethasone can help reduce serious complications and death in patients with severe burns. This trial will also look at its effects on infections and recovery times.

Severe Burns3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

COVID-19: Ibuzatrelvir Study for High-Risk Patients

We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.

COVID-193-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Cardiac Surgery: Angiotensin II vs. Noradrenaline

We are studying whether angiotensin II can better prevent kidney injury compared to noradrenaline in patients undergoing cardiac surgery. This research may help improve kidney health outcomes after surgery.

Acute Kidney Injury>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology